Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
This study is to study pharmacokinetics of Doxil using Doxil and Avastin on ovarian cancer
patients who are resistant to or have relapsed from platinum-based therapy.
Phase:
Phase 1
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health
Collaborators:
Genentech, Inc. University of New Mexico University of New Mexico Cancer Center